Scholarlink

<p>Progesterone can inhibit tumoural proliferation in oestrogen receptor positive (ER+) breast cancer. The WinPro trial (Australian New Zealand Trials Clinical Trials Registry number: ACTRN12618000928213, date of registration 01/06/2018) was a randomised, multi-centre, phase 2, window-of-opportunity trial evaluating micronised progesterone (MP) in post-menopausal women with early-stage, ER+, progesterone receptor (PR) positive, HER2- breast cancer. Patients were randomised to letrozole, letrozole and MP, or tamoxifen and MP for 14 days preoperatively. The primary endpoint was the percent proportional reduction in Ki67 (‘Ki67 suppression’) between the two letrozole groups in the per protocol population. From February 2018 to June 2024, 244 patients were enrolled. 189 patients completed per protocol: letrozole (<i>n</i> = 66, 34.9%), letrozole + MP (<i>n</i> = 64, 33.9%), and tamoxifen + MP (<i>n</i> = 59, 31.2%). There was no difference in Ki67 suppression between letrozole (88.2%) versus letrozole + MP (89.2%) (<i>p</i> = 0.39). Ki67 suppression appeared lower with tamoxifen + MP (61.5%). Hot flushes appeared less frequent with letrozole + MP (13.3%) versus letrozole (22.4%) or tamoxifen + MP (20.5%).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The WinPro trial: window-of-opportunity study of endocrine therapy with micronised progesterone in ER-positive breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月21日

查看全文
  • Lucy Haggstrom,
  • Kate Middleton,
  • Andrew Parker,
  • Davendra Segara,
  • Andrew Ong,
  • Janne Bingham,
  • Emma-Kate Carson,
  • Belinda. E. Kiely,
  • Dhanusha Sabanathan,
  • Andrew Spillane,
  • Kate Saw,
  • Aura Serrano,
  • Geoffrey J. Lindeman,
  • Alexander Swarbrick,
  • Alan Coates,
  • G. Bruce Mann,
  • Wayne Tilley,
  • Elgene Lim

摘要

Progesterone can inhibit tumoural proliferation in oestrogen receptor positive (ER+) breast cancer. The WinPro trial (Australian New Zealand Trials Clinical Trials Registry number: ACTRN12618000928213, date of registration 01/06/2018) was a randomised, multi-centre, phase 2, window-of-opportunity trial evaluating micronised progesterone (MP) in post-menopausal women with early-stage, ER+, progesterone receptor (PR) positive, HER2- breast cancer. Patients were randomised to letrozole, letrozole and MP, or tamoxifen and MP for 14 days preoperatively. The primary endpoint was the percent proportional reduction in Ki67 (‘Ki67 suppression’) between the two letrozole groups in the per protocol population. From February 2018 to June 2024, 244 patients were enrolled. 189 patients completed per protocol: letrozole (n = 66, 34.9%), letrozole + MP (n = 64, 33.9%), and tamoxifen + MP (n = 59, 31.2%). There was no difference in Ki67 suppression between letrozole (88.2%) versus letrozole + MP (89.2%) (p = 0.39). Ki67 suppression appeared lower with tamoxifen + MP (61.5%). Hot flushes appeared less frequent with letrozole + MP (13.3%) versus letrozole (22.4%) or tamoxifen + MP (20.5%).